The Experts below are selected from a list of 66 Experts worldwide ranked by ideXlab platform
Arun Malhotra - One of the best experts on this subject based on the ideXlab platform.
-
role of 99mtc Glucoheptonic Acid brain single photon emission computed tomography in differentiation of recurrent brain tumour and post radiation gliosis
Journal of Medical Imaging and Radiation Oncology, 2004Co-Authors: Sukanta Barai, Gp Bandopadhayaya, Pramod Kumar Julka, K.k. Naik, A. K. Haloi, Rajender Kumar, Ashu Seith, Arun MalhotraAbstract:Abstract Blood-brain barrier imaging of brain tumours is fast attracting interest now that it has been demonstrated that disruption of the blood-brain barrier is essential for uptake of all tumour-seeking agents. The aim of the present study was to differentiate recurrent tumour from post-radiation gliosis using (99m)technetium-glucoheptonate ((99m)Tc-GHA) as a tumour-seeking agent. Brain single photon emission computed tomography (SPECT) with (99m)Tc-GHA was performed in 73 patients with primary malignant brain tumours after radiotherapy, and the results were correlated with the clinical behaviour of the disease on follow up. The SPECT was suggestive of recurrent tumour in 55 patients. The clinical course was consistent with recurrence in 51 of the 55 patients. The clinical course was consistent with radiation necrosis in the remaining 21 patients, which included 17 patients with a negative SPECT and four patients with a positive SPECT study. Mean GHA index in recurrent tumour and post-radiation gliosis was 7.04 +/- 4.35 and 1.88 +/- 1.70, respectively (P = 0.0001). Mean GHA index in high-grade and low-grade glioma was 7.78 +/- 4.73 and 3.15 +/- 2.44, respectively (P = 0.001). (99m)Technetium-glucoheptonate brain SPECT is a sensitive and reliable diagnostic modality to differentiate recurrent tumour from post-radiation gliosis.
-
Role of 99mTc‐Glucoheptonic Acid brain single photon emission computed tomography in differentiation of recurrent brain tumour and post‐radiation gliosis
Australasian radiology, 2004Co-Authors: Sukanta Barai, Gp Bandopadhayaya, Pramod Kumar Julka, K.k. Naik, A. K. Haloi, Rajender Kumar, Ashu Seith, Arun MalhotraAbstract:Abstract Blood-brain barrier imaging of brain tumours is fast attracting interest now that it has been demonstrated that disruption of the blood-brain barrier is essential for uptake of all tumour-seeking agents. The aim of the present study was to differentiate recurrent tumour from post-radiation gliosis using (99m)technetium-glucoheptonate ((99m)Tc-GHA) as a tumour-seeking agent. Brain single photon emission computed tomography (SPECT) with (99m)Tc-GHA was performed in 73 patients with primary malignant brain tumours after radiotherapy, and the results were correlated with the clinical behaviour of the disease on follow up. The SPECT was suggestive of recurrent tumour in 55 patients. The clinical course was consistent with recurrence in 51 of the 55 patients. The clinical course was consistent with radiation necrosis in the remaining 21 patients, which included 17 patients with a negative SPECT and four patients with a positive SPECT study. Mean GHA index in recurrent tumour and post-radiation gliosis was 7.04 +/- 4.35 and 1.88 +/- 1.70, respectively (P = 0.0001). Mean GHA index in high-grade and low-grade glioma was 7.78 +/- 4.73 and 3.15 +/- 2.44, respectively (P = 0.001). (99m)Technetium-glucoheptonate brain SPECT is a sensitive and reliable diagnostic modality to differentiate recurrent tumour from post-radiation gliosis.
Mario Bernardo-filho - One of the best experts on this subject based on the ideXlab platform.
-
Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal eva uations
Human & experimental toxicology, 2001Co-Authors: M. L. Gomes, D. M. M. Mattos, R. De Souza Freitas, R Jac Bezerral, Mario Bernardo-filhoAbstract:Mitomycin C (MMC) has been used as a component of many chemotherapeutic regimens and some toxic effects of this substance have been reported. As it has been reported that the toxicological effect of a drug can alter the biodistribution of radiopharmaceuticals and because patients on chemotherapeutic treatment can be submitted to a nuclear medicine procedure, we investigated whether MMC could affect the uptake of various technetium - 99m (99mTc) radiopharmaceuticals used for renal evaluations. The purpose of this study was to suggest a model to evaluate the toxic effect of substances in specific organs. Three doses of MMC (0.45 mg) were administered to mice (N= 15). One hour after the last dose, 99mTc radiopharmaceuticals, 99mTc-diethylene-triaminepentaacetic Acid (99mTc-DTPA), 99mTc-dimercaptosuccinic Acid (99mTc-DMSA) or 99mTc-Glucoheptonic Acid (99mTc-GHA), with activity of 7.4 MBq, were also administered in the treated group and in the control group (N= 15). After another 0.5 h, the animals were sacrif...
-
Assessment of the effect of vincristine on the biodistribution of 99Tcm-labelled Glucoheptonic Acid in female Balb/c mice.
Nuclear medicine communications, 2000Co-Authors: D. M. M. Mattos, M. L. Gomes, R. S. Freitas, P. C. Rodrigues, V. D. Nascimento, Edson Boasquevisque, E. F. Paula, Mario Bernardo-filhoAbstract:There is evidence that the biodistribution and the pharmacokinetics of 99Tcm radiopharmaceuticals can be modified by some drugs, pathological states, irradiation and surgical procedures. Vincristine have been widely used in various chemotherapeutic protocols in oncology. We are trying to develop an animal model to assess the toxicology in different organs of compounds used as therapeutic drugs. We have studied the effect of vincristine on the distribution of 99Tcm-Glucoheptonic Acid (99Tcm-GHA) in female mice. After the last dose of vincristine, 99Tcm-GHA (7.4 MBq) was injected, the animals sacrificed and the percentage of radioactivity determined in the isolated organs. The percentage of activity was significantly decreased in the uterus, ovary, spleen, thymus, lymph nodes (inguinal and mesenteric), kidney and heart, but was not significantly altered in the lung, liver, pancreas, stomach, thyroid, brain and bone. Our results can be explained by the metabolic, toxic, therapeutic and immunosuppressive actions of this chemotherapeutic drug.
-
Cellular inactivation induced by a radiopharmaceutical kit : role of stannous chloride
Toxicology letters, 1998Co-Authors: Maria Luciana B. Assis, Manuela R. Caceres, Jose C.p. De Mattos, A. Caldeira-de-araújo, Mario Bernardo-filhoAbstract:Stannous chloride (SnCl2) has been used in many sectors of human activities such as food manufacturing and in nuclear medicine to produce radiopharmaceuticals labeled with technetium-99m (99mTc). Due to its importance and genotoxic potentiality, we decided to evaluate the biological effect induced by a nuclear medicine kit, which includes SnCl2, in association with Glucoheptonic Acid (GHA) which is employed for brain and renal scintigraphies. These studies were carried out with the Escherichia coli AB1157 strain and the deoxyribonucleic Acid (DNA) plasmid pUC 9.1. The experiments, with different concentrations of SnCl2 and GHA, show an inverse relationship between both agents. When the GHA concentration was increased, the cellular inactivation induced by SnCl2 was reduced, as measured by the number of viable cells. Moreover, GHA protects the DNA molecule against the damage induced by SnCl2.
A. Caldeira-de-araújo - One of the best experts on this subject based on the ideXlab platform.
-
Cellular inactivation induced by a radiopharmaceutical kit : role of stannous chloride
Toxicology letters, 1998Co-Authors: Maria Luciana B. Assis, Manuela R. Caceres, Jose C.p. De Mattos, A. Caldeira-de-araújo, Mario Bernardo-filhoAbstract:Stannous chloride (SnCl2) has been used in many sectors of human activities such as food manufacturing and in nuclear medicine to produce radiopharmaceuticals labeled with technetium-99m (99mTc). Due to its importance and genotoxic potentiality, we decided to evaluate the biological effect induced by a nuclear medicine kit, which includes SnCl2, in association with Glucoheptonic Acid (GHA) which is employed for brain and renal scintigraphies. These studies were carried out with the Escherichia coli AB1157 strain and the deoxyribonucleic Acid (DNA) plasmid pUC 9.1. The experiments, with different concentrations of SnCl2 and GHA, show an inverse relationship between both agents. When the GHA concentration was increased, the cellular inactivation induced by SnCl2 was reduced, as measured by the number of viable cells. Moreover, GHA protects the DNA molecule against the damage induced by SnCl2.
-
Stannous chloride and the Glucoheptonic Acid effect: study of a kit used in nuclear medicine.
Cancer letters, 1998Co-Authors: M L Assis, A. Caldeira-de-araújo, J B Neto, J E Souza, M Bernardo-filhoAbstract:Stannous dichloride is used as a reducing agent in the preparation of technetium-99m radiopharmaceuticals. We decided to evaluate the genotoxic potential of the tin (II)-glucoheptonate complex in the kit using a tester strain of Escherichia coli AB1157. Our results show that tin (II) chloride and the tin (II)-glucoheptonate complex exert a genotoxic effect in this system. While the genotoxic effect disappeared when the glucoheptonate concentration was increased, the glucoheptonate did not protect the cultures from the damaging effects of hydrogen peroxide. The ability of glucoheptonate to protect cultures from tin (II)-induced damage can be explained on the basis of its metal chelating properties.
Sukanta Barai - One of the best experts on this subject based on the ideXlab platform.
-
role of 99mtc Glucoheptonic Acid brain single photon emission computed tomography in differentiation of recurrent brain tumour and post radiation gliosis
Journal of Medical Imaging and Radiation Oncology, 2004Co-Authors: Sukanta Barai, Gp Bandopadhayaya, Pramod Kumar Julka, K.k. Naik, A. K. Haloi, Rajender Kumar, Ashu Seith, Arun MalhotraAbstract:Abstract Blood-brain barrier imaging of brain tumours is fast attracting interest now that it has been demonstrated that disruption of the blood-brain barrier is essential for uptake of all tumour-seeking agents. The aim of the present study was to differentiate recurrent tumour from post-radiation gliosis using (99m)technetium-glucoheptonate ((99m)Tc-GHA) as a tumour-seeking agent. Brain single photon emission computed tomography (SPECT) with (99m)Tc-GHA was performed in 73 patients with primary malignant brain tumours after radiotherapy, and the results were correlated with the clinical behaviour of the disease on follow up. The SPECT was suggestive of recurrent tumour in 55 patients. The clinical course was consistent with recurrence in 51 of the 55 patients. The clinical course was consistent with radiation necrosis in the remaining 21 patients, which included 17 patients with a negative SPECT and four patients with a positive SPECT study. Mean GHA index in recurrent tumour and post-radiation gliosis was 7.04 +/- 4.35 and 1.88 +/- 1.70, respectively (P = 0.0001). Mean GHA index in high-grade and low-grade glioma was 7.78 +/- 4.73 and 3.15 +/- 2.44, respectively (P = 0.001). (99m)Technetium-glucoheptonate brain SPECT is a sensitive and reliable diagnostic modality to differentiate recurrent tumour from post-radiation gliosis.
-
Role of 99mTc‐Glucoheptonic Acid brain single photon emission computed tomography in differentiation of recurrent brain tumour and post‐radiation gliosis
Australasian radiology, 2004Co-Authors: Sukanta Barai, Gp Bandopadhayaya, Pramod Kumar Julka, K.k. Naik, A. K. Haloi, Rajender Kumar, Ashu Seith, Arun MalhotraAbstract:Abstract Blood-brain barrier imaging of brain tumours is fast attracting interest now that it has been demonstrated that disruption of the blood-brain barrier is essential for uptake of all tumour-seeking agents. The aim of the present study was to differentiate recurrent tumour from post-radiation gliosis using (99m)technetium-glucoheptonate ((99m)Tc-GHA) as a tumour-seeking agent. Brain single photon emission computed tomography (SPECT) with (99m)Tc-GHA was performed in 73 patients with primary malignant brain tumours after radiotherapy, and the results were correlated with the clinical behaviour of the disease on follow up. The SPECT was suggestive of recurrent tumour in 55 patients. The clinical course was consistent with recurrence in 51 of the 55 patients. The clinical course was consistent with radiation necrosis in the remaining 21 patients, which included 17 patients with a negative SPECT and four patients with a positive SPECT study. Mean GHA index in recurrent tumour and post-radiation gliosis was 7.04 +/- 4.35 and 1.88 +/- 1.70, respectively (P = 0.0001). Mean GHA index in high-grade and low-grade glioma was 7.78 +/- 4.73 and 3.15 +/- 2.44, respectively (P = 0.001). (99m)Technetium-glucoheptonate brain SPECT is a sensitive and reliable diagnostic modality to differentiate recurrent tumour from post-radiation gliosis.
M Bernardo-filho - One of the best experts on this subject based on the ideXlab platform.
-
Stannous chloride and the Glucoheptonic Acid effect: study of a kit used in nuclear medicine.
Cancer letters, 1998Co-Authors: M L Assis, A. Caldeira-de-araújo, J B Neto, J E Souza, M Bernardo-filhoAbstract:Stannous dichloride is used as a reducing agent in the preparation of technetium-99m radiopharmaceuticals. We decided to evaluate the genotoxic potential of the tin (II)-glucoheptonate complex in the kit using a tester strain of Escherichia coli AB1157. Our results show that tin (II) chloride and the tin (II)-glucoheptonate complex exert a genotoxic effect in this system. While the genotoxic effect disappeared when the glucoheptonate concentration was increased, the glucoheptonate did not protect the cultures from the damaging effects of hydrogen peroxide. The ability of glucoheptonate to protect cultures from tin (II)-induced damage can be explained on the basis of its metal chelating properties.